Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
$8.24
$0.10(1.66%)
At close: 4:00 PM EST
$8.24
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$4.60 - $12.62
Previous CloseN/A
Volume37.28K
Average Volume (3M)77.23K
Market Cap
$145.16M
Enterprise Value$116.79M
Total Cash (Recent Filing)$20.61M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 27, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,489,515
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-5.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-134.86
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$15.50Price Target Upside88.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe trial passed the futility hurdle, indicating a positive Independent Data Monitoring Committee review.
Immune ResponseELI-002 7P elicits a meaningfully greater T cell response, potentially leading to longer survival and reduced disease progression.
Market PotentialModel changes include modestly raising the market penetration to 50% from 40%, and raising the trading multiple to 5X from 3X.
Bears Say
Clinical Trial DelaysThe readout timeline for the Phase 2 data has been postponed, indicating longer than expected disease-free survival in the treatment arm.
Data TransparencyThe company remains blinded to the Phase 2 trial clinical efficacy outcomes.
Investor ReactionsStock slightly pulled back on that day as some investors expected early stoppage of the trial due to a low hazard ratio at this interim analysis.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $4.60 and its highest was $12.62 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $145.16M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Mar 27, 2026 which is in 76 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.12.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 17,489,515 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -0.871%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
87.48%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$15.50
▲(88.11% Upside)
Technical Analysis
Compugen
―
Cassava Sciences
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
32.06% Insiders
2.94% Mutual Funds
3.95% Other Institutional Investors
58.57% Public Companies and
Individual Investors